New drug aims to slow kidney damage in patients with high uric acid
Disease control
Not yet recruiting
This study tests a new medicine called ABP-671 in 80 adults with chronic kidney disease and high uric acid levels. Participants will receive either the drug or a placebo for 40 weeks. The main goal is to see if the drug reduces protein in the urine, a sign of kidney damage.
Phase: PHASE2 • Sponsor: Atom Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC